



ISEC HEALTHCARE LTD.

Company Registration Number: 201400185H
(Incorporated in Singapore on 2 January 2014)

CESSATION OF EYE CLINIC IN MOUNT ELIZABETH NOVENA SPECIALIST CENTRE

The Board of Directors (the “**Board**”) of ISEC Healthcare Ltd. (the “**Company**” and together with its subsidiaries the “**Group**”) wishes to announce that its wholly-owned subsidiary in Singapore, International Specialist Eye Centre Pte. Ltd. (“**ISEC Singapore**”) will be ceasing its eye clinic operation in Mount Elizabeth Novena Specialist Centre from December 2015. ISEC Singapore shall remain a dormant company thereafter.

ISEC Singapore was incorporated in January 2014 to operate the business of an eye centre under the ISEC brand-name in Mount Elizabeth Novena Specialist Centre in partnership with three doctors (the “**Partner Doctors**”). Since the commencement of its business operation in August 2014, ISEC Singapore had been loss-making and is expected to continue to be loss-making for the financial year ending 31 December 2015 (“**FY2015**”).

Together with the Partner Doctors, the management of the Company (the “**Management**”) had explored various options in recent months to reduce ISEC Singapore’s operating expenses. Despite extensive negotiations, the Partner Doctors in ISEC Singapore have not reached any agreement with Management to continue their professional practice in ISEC Singapore based on proposed revised remuneration terms. The three doctors practising at ISEC Singapore, including the Medical Director of ISEC Singapore, Dr Cordelia Chan, had tendered their resignation on 30 June 2015. Dr Cordelia Chan will cease to be a key executive officer of the Company with effect from 31 December 2015, and the details and declarations of Dr Cordelia Chan as required under Rule 704(6) of Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited are contained in a separate announcement made today.

In connection with the aforesaid and taking into consideration the challenging business prospects and existing high cost structure of ISEC Singapore, the Board is of the view that it is in the best interest of the Company to cease the business operations of ISEC Singapore. Nevertheless, the Board recognises that Singapore remains an important market for the healthcare business and the Group shall continue to maintain an active presence through its other established and profitable clinic in Singapore, operated under ISEC Eye Pte. Ltd. (“**ISEC Eye**”), where ISEC Eye provides its services in Lee Hung Ming Eye Centre at Gleneagles Hospital, Singapore. Further, the Group will continue to seek for expansion strategies in the Asia Pacific region.

In view of the intended cessation of the business in ISEC Singapore, the Board expects losses and closure related cost of approximately SGD2.6 million for ISEC Singapore for FY2015. The aforementioned losses and closure related costs for ISEC Singapore is expected to have a material impact on the consolidated earnings per share (“**EPS**”) and non-material impact on net tangible assets per share (“**NTA**”) of the Group for FY2015. Nevertheless, the Group is expected to reap cost savings of approximately SGD1.3 million, which is expected to have a positive impact on the EPS and/or NTA of the Group for the financial year ending 31 December 2016 following the discontinued operations of ISEC Singapore.

By Order of the Board

Dr Wong Jun Shyan
Executive Director and Chief Executive Officer
10 July 2015

*ISEC Healthcare Ltd. (the "**Company**") was listed on Catalist of the Singapore Exchange Securities Trading Limited (the "**SGX-ST**") on 28 October 2014. The initial public offering of the Company (the "**IPO**") was sponsored by PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**" or "**PPCF**").*

This announcement has been prepared by the Company and its contents have been reviewed by the Sponsor for compliance with the SGX-ST Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement.

This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Keng Yeng Pheng, Associate Director, Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.